Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 2: Aging and Survival.

Slides:



Advertisements
Similar presentations
SC968: Panel Data Methods for Sociologists
Advertisements

April 25 Exam April 27 (bring calculator with exp) Cox-Regression
Intermediate methods in observational epidemiology 2008 Instructor: Moyses Szklo Measures of Disease Frequency.
Main Points to be Covered
Lecture 3 Survival analysis. Problem Do patients survive longer after treatment A than after treatment B? Possible solutions: –ANOVA on mean survival.
Point and Confidence Interval Estimation of a Population Proportion, p
Biostatistics in Research Practice Time to event data Martin Bland Professor of Health Statistics University of York
Samuel Clark Department of Sociology, University of Washington Institute of Behavioral Science, University of Colorado at Boulder Agincourt Health and.
Vanderbilt Sports Medicine Chapter 4: Prognosis Presented by: Laurie Huston and Kurt Spindler Evidence-Based Medicine How to Practice and Teach EBM.
Main Points to be Covered Cumulative incidence using life table method Difference between cumulative incidence based on proportion of persons at risk and.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
EVIDENCE BASED MEDICINE
SMRs, PMRs and Survival Measures Principles of Epidemiology Lecture 3 Dona SchneiderDona Schneider, PhD, MPH, FACE.
Assessing Survival: Cox Proportional Hazards Model Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Analysis of Complex Survey Data
Survival Analysis Diane Stockton. Survival Curves Y axis, gives the proportion of people surviving from 1 at the top to zero at the bottom, representing.
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.
Lecture 3: Measuring the Occurrence of Disease
01/20141 EPI 5344: Survival Analysis in Epidemiology Quick Review and Intro to Smoothing Methods March 4, 2014 Dr. N. Birkett, Department of Epidemiology.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
Survival Data John Kornak March 29, 2011
Lecture 3 Survival analysis.
Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 4: Taking Risks and Playing the Odds: OR vs.
Inference for a Single Population Proportion (p).
1 POPULATION PROJECTIONS Session 2 - Background & first steps Ben Jarabi Population Studies & Research Institute University of Nairobi.
Biostatistics in Practice Peter D. Christenson Biostatistician LABioMed.org /Biostat Session 2: Summarization of Quantitative Information.
1 Introduction to medical survival analysis John Pearson Biostatistics consultant University of Otago Canterbury 7 October 2008.
Prevalence The presence (proportion) of disease or condition in a population (generally irrespective of the duration of the disease) Prevalence: Quantifies.
Assessing Survival: Cox Proportional Hazards Model
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 2: Diagnostic Classification.
Correlation and Linear Regression. Evaluating Relations Between Interval Level Variables Up to now you have learned to evaluate differences between the.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 3: Incomplete Data in Longitudinal Studies.
Biostatistics Case Studies 2008 Peter D. Christenson Biostatistician Session 5: Choices for Longitudinal Data Analysis.
INTRODUCTION TO SURVIVAL ANALYSIS
Chapter 12 Survival Analysis.
01/20151 EPI 5344: Survival Analysis in Epidemiology Epi Methods: why does ID involve person-time? March 10, 2015 Dr. N. Birkett, School of Epidemiology,
01/20141 EPI 5344: Survival Analysis in Epidemiology Epi Methods: why does ID involve person-time? March 13, 2014 Dr. N. Birkett, Department of Epidemiology.
HSRP 734: Advanced Statistical Methods July 17, 2008.
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
Epidemiology: Basic concepts and principles ENV
TYPES There are several TYPES of variables that reflect characteristics of the data Ratio Interval Ordinal Nominal.
Censoring an observation of a survival r.v. is censored if we don’t know the survival time exactly. usually there are 3 possible reasons for censoring.
Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 6: “Number Needed to Treat” to Prevent One Case.
Medical Statistics as a science
Statistics : Statistical Inference Krishna.V.Palem Kenneth and Audrey Kennedy Professor of Computing Department of Computer Science, Rice University 1.
Introduction to Inference: Confidence Intervals and Hypothesis Testing Presentation 4 First Part.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 3: Testing Hypotheses.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 4: Study Size for Precision or Power.
Lecture 5: The Natural History of Disease: Ways to Express Prognosis
01/20151 EPI 5344: Survival Analysis in Epidemiology Actuarial and Kaplan-Meier methods February 24, 2015 Dr. N. Birkett, School of Epidemiology, Public.
01/20151 EPI 5344: Survival Analysis in Epidemiology Cox regression: Introduction March 17, 2015 Dr. N. Birkett, School of Epidemiology, Public Health.
Biostatistics in Practice Session 2: Summarization of Quantitative Information Peter D. Christenson Biostatistician
12/20091 EPI 5240: Introduction to Epidemiology Incidence and survival December 7, 2009 Dr. N. Birkett, Department of Epidemiology & Community Medicine,
Measures of Disease Frequency
Biostatistics Case Studies 2014 Youngju Pak Biostatistician Session 5: Survival Analysis Fundamentals.
Leicester Warwick Medical School Health and Disease in Populations Cohort Studies Paul Burton.
01/20151 EPI 5344: Survival Analysis in Epidemiology Quick Review from Session #1 March 3, 2015 Dr. N. Birkett, School of Epidemiology, Public Health &
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 3: An Alternative to Last-Observation-Carried-Forward:
2000 SEMINAR ON REINSURANCE PITFALLS IN FITTING LOSS DISTRIBUTIONS CLIVE L. KEATINGE.
01/20151 EPI 5344: Survival Analysis in Epidemiology Hazard March 3, 2015 Dr. N. Birkett, School of Epidemiology, Public Health & Preventive Medicine,
INTRODUCTION TO CLINICAL RESEARCH Survival Analysis – Getting Started Karen Bandeen-Roche, Ph.D. July 20, 2010.
Biostatistics Case Studies 2009 Peter D. Christenson Biostatistician Session 2: Survival Analysis Fundamentals.
02/20161 EPI 5344: Survival Analysis in Epidemiology Hazard March 8, 2016 Dr. N. Birkett, School of Epidemiology, Public Health & Preventive Medicine,
DURATION ANALYSIS Eva Hromádková, Applied Econometrics JEM007, IES Lecture 9.
Inference for a Single Population Proportion (p)
Biostatistics Case Studies 2007
April 18 Intro to survival analysis Le 11.1 – 11.2
Chapter 4 SURVIVAL AND LIFE TABLES
Presentation transcript:

Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 2: Aging and Survival

Case Study

Cancer Registry + Medicare Records Death reports through 2002: Maximum follow-up = 10 years. Diagnosed

Follow Up Time

Life Expectancy: Mean Time from Diagnosis to Any Cause of Death How many men were in these subgroups? Calculated?

Some Subgroup Sizes ~35,755 x 0.40 x x x / 3 = ~100 ~105 ~ 40 ~ 86 ~ 96 ~ 36

Life Expectancy: More Detail N < 110 at each age N < 100 at each age N < 45 at each age

Summary So Far This subgroup has ~100 men followed ≤10 years, mean follow-up < 7 years, N=? died. Mean time to death extrapolated to over 9 years beyond maximum follow-up with apparently good precision. How was 19.1 years determined?

A Fixed Cohort Approach as in clinical trial, but add extrapolation Extrapolated Median Years to Death 95% “CI” Fitted Assumed Model Not Done here: With N=100, likely more error than is depicted. 95% Confidence Bands

Fixed Cohort Approach If followed long enough or deaths occur fast enough, would not need to extrapolate. Otherwise, would require specifying a model for the survival curve in order to extrapolate. Confidence intervals become wide even with minor extrapolation and do not incorporate uncertainty in the chosen model. The stepped Kaplan-Meier “curve” is the real data. Let’s review Kaplan-Meier before continuing with the paper.

Kaplan-Meier: Cumulated Probabilities Suppose that we want the probability of surviving for 5 years. If no subjects dropped by 5 years, then this prob is the same as the proportion of subjects alive at that time. If some subjects are lost to us before 5 years, then we cannot use the proportion because we don’t know the outcome for the dropped subjects, and hence the numerator. We can divide the 5 years into intervals using the dropped times as interval endpoints. Ns are different in these intervals. Then, find proportions surviving in each interval and cumulate by multiplying these proportions to get the survival probability. See next slide for example.

Kaplan-Meier: Cumulated Probabilities The survival curve below for made-up data for 100 subjects gives the probability of being alive at 5 years as about Suppose 9 subjects dropped at 2 years and 7 dropped at 4 yrs and 20, 20, and 17 died in the intervals 0-2, 2-4, 4-5 yrs. Then, the 0-2 yr interval has 80/100 surviving. The 2-4 interval has 51/71 surviving; 4-5 has 27/44 surviving. So, 5-yr survival prob is (80/100)(51/71)(27/44)= Actually uses finer subdivisions than 0-2, 2-4, 4-5 years, with exact death times.

Fixed Cohort with Complete Follow Up Fixed N at age 67, no dropout, everyone has a time to death: We have a direct mean time to death = Total Follow-Up/N = PY/N. Mortality rate = N/PY = 1/MeanTime N N Subject # Age Death at end of line. Sum of line lengths = PY.

Complete Follow Up Usually Unlikely Unlikely to be able to follow a single cohort so long: Suppose we have death records for one year for everyone 67 or older. Find N died and PY → MeanTime = PY/N. Follow up times are still for ≥67 years, but now, from different birth cohorts, i.e., persons 67 at different calendar times. Can generalize to more than 1 year of records, as in this study. Actuarial or life table methods - next slide.

General Life Table Method Age of Death % Die Cum % Survive = 0.90* = 0.72* = 0.61* = 0.02* *N with this F/U 0.90*0.20*N with this F/U 0.72*0.15*N with this F/U Sum of line lengths = PY. Mean time = PY/N. Age Made-up Data Has structure of the fixed cohort with complete follow up:

Life Table Method Cont’d Again, in general, follow up contributions are from different birth cohorts. Here, for age-specific time of diagnosis, birth cohorts are <10 years apart. Does not consider chronic conditions developed after diagnosis. Here, neither fixed cohort with complete follow up, nor general life table with all ages included. Does that matter? Next slide.

Life Table without All Age Groups Suppose there were uniform times of death between 67 and 101 years of age: N N Subject # Age There are an equal number of deaths in both periods, but much more follow up in 67-84, so if a fixed cohort study ends before complete follow up, the mortality rate = deaths/PY is an under estimate. However, mortality from life table is valid if rate of diagnoses are in steady state over time

Proportional Hazards Survival Analysis Kaplan-Meier curves use raw data - no modeling. Need separate curve for any subgroup. Cannot use for sparse subgroups due to high stratification or adjustment for factors on a continuum. Note use of proportional hazards model instead of Kaplan-Meier to make multiple adjustments:

Proportional Hazards Survival Analysis Hazard ~= short-term incidence (deaths/person-time) at time t; i.e., is a function over time. Hazard may increase or decrease over time, e.g., aging effects and removing the frail. Constant hazard → exponential survival curve. Hazard function for a baseline condition is unconstrained. The model forces hazards for other conditions to be proportional to it at all times. This is “semi-parametric”. There is not a fitted functional form like exponential, but more structure than Kaplan-Meier is imposed.

Proportional Hazards Survival Analysis Time Hazard FunctionsSurvival Curves Time Surv Prob Proportionality assumption forces structure on survival probabilities that Kaplan-Meier does not. Validity of the assumption can be checked with the data. h=b h=5b h=7b 0 Chronic conditions 1-2 Chronic conditions ≥3 Chronic conditions 46% 37% 25%